GlassScriptPhysician profile
Jason M Radecke
NPI 1568643013
$88,375.11
in general payments reported to CMS, 2019-2025
11 companies · $8,039 in 2025
The $8,039 reported for 2025 was more than what 94% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.17 · 2021: $20K · 2022: $25K · 2023: $24K · 2024: $11K · 2025: $8,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $40K · Travel and Lodging: $2,627 · Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $40,012.12 |
| Travel and Lodging | $2,626.50 |
| Food and Beverage | $1,212.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $56,266.20 | 2021-2025 | Enseal, Megadyne, Harmonic |
| Ethicon US, LLC | $18,615.83 | 2021-2025 | Harmonic, Enseal, Megadyne |
| Ethicon INC. | $13,105.00 | 2021-2023 | Harmonic, Enseal, Megadyne |
| Hologic Sales and Service, LLC | $108.16 | 2023-2025 | Localizer, Magtrace, Magseed |
| Tela Bio, INC. | $86.16 | 2023-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Heron Therapeutics, INC. | $54.68 | 2022-2023 | Zynrelef |
| Biocomposites INC | $50.41 | 2024 | |
| Intuitive Surgical, INC. | $30.64 | 2024 | |
| Merck Sharp & Dohme LLC | $21.90 | 2025 | Keytruda, Lynparza |
| Kci USA, INC. | $18.17 | 2019 | |
| Stryker Corporation | $17.96 | 2025 | Molli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Radecke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.